JPWO2022002153A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022002153A5 JPWO2022002153A5 JP2022580273A JP2022580273A JPWO2022002153A5 JP WO2022002153 A5 JPWO2022002153 A5 JP WO2022002153A5 JP 2022580273 A JP2022580273 A JP 2022580273A JP 2022580273 A JP2022580273 A JP 2022580273A JP WO2022002153 A5 JPWO2022002153 A5 JP WO2022002153A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010619111.6 | 2020-06-30 | ||
| CN202010620778 | 2020-06-30 | ||
| CN202010619083.8 | 2020-06-30 | ||
| CN202010619083 | 2020-06-30 | ||
| CN202010620778.8 | 2020-06-30 | ||
| CN202010619111 | 2020-06-30 | ||
| PCT/CN2021/103687 WO2022002153A1 (zh) | 2020-06-30 | 2021-06-30 | 用于治疗肿瘤的药物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023531090A JP2023531090A (ja) | 2023-07-20 |
| JPWO2022002153A5 true JPWO2022002153A5 (https=) | 2024-07-09 |
| JP2023531090A5 JP2023531090A5 (https=) | 2024-07-09 |
| JP7799638B2 JP7799638B2 (ja) | 2026-01-21 |
Family
ID=79317451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580273A Active JP7799638B2 (ja) | 2020-06-30 | 2021-06-30 | 腫瘍を治療するための薬物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230310596A1 (https=) |
| EP (1) | EP4174087A4 (https=) |
| JP (1) | JP7799638B2 (https=) |
| CN (1) | CN115698076A (https=) |
| AU (1) | AU2021301947A1 (https=) |
| CA (1) | CA3188017A1 (https=) |
| WO (1) | WO2022002153A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116209443A (zh) * | 2021-08-05 | 2023-06-02 | 正大天晴药业集团股份有限公司 | 治疗小细胞肺癌的药物组合 |
| CN119278053A (zh) * | 2022-06-02 | 2025-01-07 | 正大天晴药业集团股份有限公司 | 用于治疗子宫恶性肿瘤的药物组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US9751859B2 (en) * | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| CN107460221B (zh) * | 2016-06-02 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法 |
| CN110573172A (zh) * | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| US20210147547A1 (en) * | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CN113861295B (zh) * | 2018-07-20 | 2024-05-24 | 厦门大学 | 抗pd-1抗体及其用途 |
| AU2020212767B2 (en) * | 2019-01-25 | 2025-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combined pharmaceutical composition for treating tumor |
| CN112168961A (zh) * | 2019-07-03 | 2021-01-05 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗结直肠癌的联用药物组合物 |
-
2021
- 2021-06-30 WO PCT/CN2021/103687 patent/WO2022002153A1/zh not_active Ceased
- 2021-06-30 CA CA3188017A patent/CA3188017A1/en active Pending
- 2021-06-30 EP EP21833511.5A patent/EP4174087A4/en active Pending
- 2021-06-30 US US18/003,718 patent/US20230310596A1/en active Pending
- 2021-06-30 AU AU2021301947A patent/AU2021301947A1/en active Pending
- 2021-06-30 JP JP2022580273A patent/JP7799638B2/ja active Active
- 2021-06-30 CN CN202180041400.5A patent/CN115698076A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4019019B1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2019517549A5 (https=) | ||
| CN111065411A (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| WO2018068691A1 (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2021518394A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN107849128A (zh) | 瘙痒治疗 | |
| CN115698076A (zh) | 用于治疗肿瘤的药物 | |
| JPWO2022002153A5 (https=) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| RU2019108441A (ru) | Режим дозирования | |
| US20200009104A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an antitumor platinium complex, and an immune checkpoint modulator | |
| JPWO2023041622A5 (https=) | ||
| CN115487188A (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| JPWO2020012244A5 (https=) | ||
| JPWO2021214253A5 (https=) | ||
| JPWO2023011631A5 (https=) | ||
| HK40075828B (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| JPWO2021087016A5 (https=) |